| Literature DB >> 25893644 |
Wei-Hua Tang1, Chao-Ping Wang2, Fu-Mei Chung2, Lynn L H Huang3, Teng-Hung Yu2, Wei-Chin Hung2, Li-Fen Lu4, Po-Yuan Chen5, Ching-Hsing Luo5, Kun-Tai Lee1, Yau-Jiunn Lee6, Wen-Ter Lai1.
Abstract
Total mortality and sudden cardiac death is highly prevalent in patients with chronic kidney disease (CKD). In CKD patients, the protein-bound uremic retention solute indoxyl sulfate (IS) is independently associated with cardiovascular disease. However, the underlying mechanisms of this association have yet to be elucidated. The relationship between IS and cardiac electrocardiographic parameters was investigated in a prospective observational study among early CKD patients. IS arrhythmogenic effect was evaluated by in vitro cardiomyocyte electrophysiological study and mathematical computer simulation. In a cohort of 100 early CKD patients, patients with corrected QT (QTc) prolongation had higher IS levels. Furthermore, serum IS level was independently associated with prolonged QTc interval. In vitro, the delay rectifier potassium current (IK) was found to be significantly decreased after the treatment of IS in a dose-dependent manner. The modulation of IS to the IK was through the regulation of the major potassium ion channel protein Kv 2.1 phosphorylation. In a computer simulation, the decrease of IK by IS could prolong the action potential duration (APD) and induce early afterdepolarization, which is known to be a trigger mechanism of lethal ventricular arrhythmias. In conclusion, serum IS level is independently associated with the prolonged QTc interval in early CKD patients. IS down-regulated IK channel protein phosphorylation and the IK current activity that in turn increased the cardiomyocyte APD and QTc interval in vitro and in the computer ORd model. These findings suggest that IS may play a role in the development of arrhythmogenesis in CKD patients.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25893644 PMCID: PMC4403985 DOI: 10.1371/journal.pone.0119545
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patient demographics of 100 chronic kidney disease patients.
| Age (years) | 61 (54–69) |
| Men/Women (n, %) | 56/44 (56/44) |
| Hypertension (% yes/no) | 65/35 |
| Diabetes mellitus (% yes/no) | 22/78 |
| Hyperlipidemia (% yes/no) | 53/47 |
| Current smoking (% yes/no) | 32/68 |
| Body mass index (kg/m2) | 25.2 ± 3.6 |
| Systolic blood pressure (mmHg) | 129 ± 19 |
| Diastolic blood pressure (mmHg) | 75 ± 11 |
| Fasting sugar (mg/dl) | 111.2 ± 37.3 |
| Total cholesterol (mg/dl) | 181.0 ± 41.6 |
| Triglyceride (mg/dl) | 154.7 (77.5–173.5) |
| HDL-cholesterol (mg/dl) | 44.8 ± 12.9 |
| LDL-cholesterol (mg/dl) | 106.1 ± 37.2 |
| Hematocrit (%) | 40.3 ± 4.6 |
| Creatinine (mg/dl) | 1.4 ± 0.9 |
| GFR-MDRDGFR-E (ml/min/1.73m2) | 63.0 ± 14.6 |
| Albumin (mg/dl) | 4.1 ± 0.3 |
| Indoxyl sulfate (μmol/L) | 6.1 (0.9–6.1) |
| Hs-CRP (mg/L) | 4.8 (0.8–4.0) |
| Electrocardiographic parameters | |
| Rate (bpm) | 73.0 ± 16.3 |
| PR interval (ms) | 161.5 ± 24.2 |
| QRS duration (ms) | 94.0 ± 17.3 |
| QT interval (ms) | 401.8 ± 44.6 |
| QTc interval (ms) | 436.7 ± 40.4 |
Values expressed as number (percent), mean ±SD, or median (25th to 75th percentile), as appropriate. Bpm: beats per minute, HDL: high-density lipoprotein, LDL: low-density lipoprotein, Hs-CRP: high-sensitivity C-reactive protein.
Clinical and biochemical variables associated in univariate analysis with log indoxyl sulfate.
| Variable | Unit | β Coefficient (confidence interval) | p value |
|---|---|---|---|
| Age | year | 0.329 (0.006 to 0.023) | 0.001 |
| Sex | Men | 0.115 (-0.076 to 0.286) | 0.253 |
| Hypertension | Yes (65) | 0.057 (-0.135 to 0.243) | 0.573 |
| Diabetes mellitus | Yes (22) | 0.182 (-0.017 to 0.412) | 0.070 |
| Hyperlipidemia | Yes (53) | 0.017 (-0.166 to 0.196) | 0.868 |
| Current smoking | Yes (32) | 0.059 (-0.136 to 0.249) | 0.561 |
| Body mass index | kg/m2 | -0.124 (-0.041 to 0.010) | 0.218 |
| Systolic blood pressure | mmHg | 0.048 (-0.004 to 0.006) | 0.633 |
| Diastolic blood pressure | mmHg | -0.171 (-0.016 to 0.001) | 0.088 |
| Fasting sugar | mg/dl | 0.031 (-0.002 to 0.003) | 0.770 |
| Total cholesterol | mg/dl | -0.160 (-0.004 to 0.000) | 0.116 |
| Triglyceride | mg/dl | 0.037 (-0.269 to 0.391) | 0.714 |
| HDL-cholesterol | mg/dl | -0.070 (-0.009 to 0.005) | 0.500 |
| LDL-cholesterol | mg/dl | -0.201 (-0.005 to 0.000) | 0.051 |
| Hematocrit | % | -0.237 (-0.045 to -0.003) | 0.025 |
| Creatinine | mg/dl | 0.524 (0.954 to 1.878) | <0.001 |
| Estimated GFR | ml/min/1.73m2 | -0.521 (-0.021 to -0.009) | <0.001 |
| Albumin | mg/dl | -0.273 (-0.629 to -0.050) | 0.022 |
| Hs-CRP | mg/L | -0.067 (-0.018 to 0.010) | 0.580 |
| ECG rate | bpm | 0.102 (-0.003 to 0.008) | 0.310 |
| PR interval | ms | 0.047 (-0.003 to 0.005) | 0.656 |
| QRS duration | ms | 0.351 (0.004 to 0.014) | <0.001 |
| QT interval | ms | 0.237 (0.000 to 0.004) | 0.018 |
| QTc interval | ms | 0.336 (0.002–0.006) | 0.001 |
HDL: high-density lipoprotein, LDL: low-density lipoprotein.
Patient clinical laboratory data according to QTc classification.
| QTc <450 ms in women / <460 ms in men | QTc ≥450 ms in women / ≥460 ms in men | p-value | |
|---|---|---|---|
| No | 74 | 26 | |
| Age (years) | 59.0 ± 9.0 | 66.4 ± 11.4 | 0.002 |
| Sex (male/female) | 44/30 | 12/14 | 0.260 |
| Current smoking (n, %) | 23 (31.1) | 9 (34.6) | 0.805 |
| BMI (kg/m2) | 25.0 ± 3.2 | 25.7 ± 4.3 | 0.437 |
| Systolic BP (mmHg) | 128 ± 14 | 130 ± 31 | 0.620 |
| Diastolic BP (mmHg) | 76 ± 10 | 73 ± 13 | 0.341 |
| Fasting glucose (mg/dl) | 105.8 ± 23.9 | 126.8 ± 59.4 | 0.300 |
| Total cholesterol (mg/dl) | 184.3 ± 36.5 | 170.8 ± 54.0 | 0.071 |
| Triglyceride (mg/dl) | 103.5 (74.5–173.5) | 112.0 (81.8–176.5) | 0.506 |
| HDL-cholesterol (mg/dl) | 46.1 ± 12.1 | 40.5 ± 14.6 | 0.007 |
| LDL-cholesterol (mg/dl) | 107.6 ± 31.5 | 101.3 ± 51.8 | 0.216 |
| NA (mEq/L) | 139.9 ± 2.5 | 139.0 ± 4.0 | 0.190 |
| K (mEq/L) | 4.0 ± 0.8 | 4.0 ± 0.6 | 0.682 |
| Calcium (mg/dl) | 8.5 ± 1.1 | 8.8 ± 0.7 | 0.184 |
| Hematocrit (%) | 40.6 ± 4.6 | 39.5 ± 4.5 | 0.293 |
| Creatinine (mg/dl) | 1.1 (1.0–1.2) | 1.1 (1.0–1.7) | 0.157 |
| Albumin (mg/dl) | 4.1 ± 0.3 | 4.0 ± 0.4 | 0.218 |
| Estimated GFR (ml/min/1.73m2) | 64.6 ± 12.2 | 57.8 ± 20.1 | 0.343 |
| Indoxyl sulfate (μmol/L) | 2.8 (0.9–5.2) | 6.1 (0.9–11.3) | 0.019 |
Data are expressed as mean ± SD, number (%), or median (interquartile range). BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Multiple logistic regression analysis with presence of prolonged QTc interval as the dependent variable.
| exp(B) | 95% Confidence Interval | p-value | |
|---|---|---|---|
| Age | 4.94 | 1.04–2.44 | 0.045 |
| Sex | 0.05 | 0.01–0.59 | 0.017 |
| BMI | 1.12 | 0.91–1.38 | 0.285 |
| Systolic BP | 1.02 | 0.98–1.06 | 0.424 |
| Diastolic BP | 0.97 | 0.91–1.05 | 0.458 |
| Fasting glucose | 1.02 | 0.99–1.04 | 0.087 |
| Total cholesterol | 1.02 | 0.95–1.09 | 0.547 |
| Triglyceride | 0.99 | 0.98–1.01 | 0.312 |
| HDL-cholesterol | 0.95 | 0.86–1.04 | 0.270 |
| LDL-cholesterol | 0.98 | 0.92–1.05 | 0.548 |
| Smoking | 9.19 | 0.91–10.16 | 0.061 |
| Na | 0.89 | 0.66–1.19 | 0.428 |
| K | 0.55 | 0.18–1.66 | 0.285 |
| Calcium | 1.50 | 0.63–3.56 | 0.358 |
| Indoxyl sulfate | 7.35 | 1.12–4.48 | 0.037 |
BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Fig 1The effect of IS on H9c2 cardiomyocyte I and potassium channel protein Kv2.1 expression.
(A) The representative current traces for delayed rectifier potassium outward currents (I ) in H9c2 cells with different indoxyl sulfate (IS) concentration treatment. I were elicited by 300 ms depolarizing step pulses from -70 to 50 mV at a holding potential of -60 mV. (B) The average relationships between I (pA/pF) and membrane potential in the control, 0.1μM IS, 1 μM IS and 300μM IS groups (n = 6 for each groups) comparing the IS treated group with the control group, I was significantly decreased at membrane potentials from 0 mV to 50 mV in a dose-dependent manner. (C and D) The expression of Kv2.1 and phosphorylated Kv2.1 by Western blot in the H9c2 cells treated with different concentration of IS (0.1μM, 1 μM and 300μM). The expressions of Kv2.1 were not significantly different among the control and IS-treated groups (C). However, the phosphorylated Kv2.1 was significantly decreased in the 1 μM IS-and 300 μM-IS treated groups (D). (n = 6 for each groups) *: p<0.05 as compared with the control group.
Fig 2Ventricular cardiomyocyte action potential (AP) and pseudo-ECG constructed by the O'Hara-Rudy dynamic human ventricular model.
The suppression of inward rectifier potassium current (I ) mimics the effect of indoxyl sulfate toxicity to ventricular cardiomyocyte AP. The AP duration was gradually increased and the QT interval was also prolonged with the increment of I suppression. The early afterdepolarization was noted in the higher suppression of I especially in the mid-myocardial cardiomyocyte (arrow). The ventricular arrhythmias like ECG was also noted when the I was severely suppressed (empty arrow).